2nd Dec 2015 14:10
LONDON (Alliance News) - GlaxoSmithKline PLC on Wednesday said Nucala, or mepolizumab, the first biologic add-on therapy for people 12 years and older with severe asthma with an eosinophilic phenotype, is now available by prescription in the US.
Nucala is not indicated for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.
Nucala, administered by a healthcare professional as a 100mg fixed dose subcutaneous injection every 28 days, is offered to healthcare providers through a network of GSK-authorized wholesalers, specialty distributors, and specialty pharmacies.
It is estimated that in the US, asthma affects 25.7 million individuals.
Copyright RTT News/dpa-AFX
Related Shares:
Glaxosmithkline